ArticleEuropean journal of rheumatology2026
Anti IL-6 Treatment for Calcium Pyrophosphate Disease Report of 4 Cases and a Short Literature Review.
Article in European journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcium pyrophosphate deposition disease (CPPD) is a prevalent cause of inflammatory arthritis in older adults, often complicated by comorbidities that limit standard anti-inflammatory therapies. Despite its burden, evidence for biologic treatments remains limited. Four patients with CPPD, 3 with chronic polyarthritis, and 1 with overlapping gout are presented. All patients were treated with tocilizumab (TCZ) after failure or intolerance to colchicine, non-steroidal anti-inflammatory drugs, or corticosteroids. All patients experienced partial clinical improvement, with reduced inflammation markers and modest reductions in flare frequency or severity. However, corticosteroid dependence persisted in most cases, and the improvement assessment was mostly subjective. Tocilizumab was well tolerated without serious adverse events. Recent reports suggest a potential role for IL-6 blockade in CPPD, yet efficacy remains variable. Comparative studies with Interleukin (IL)-1 inhibitors and emerging data from observational cohorts and pilot trials support further investigation. In conclusion, TCZ may offer clinical benefit in refractory CPPD, while there is a true need for validation in controlled prospective studies. Cite this article as: Bieber A, Tropea A, Brikman S, Palumbo A, Atzeni F. Anti IL-6 treatment for calcium pyrophosphate disease report of 4 cases and a short literature review. Eur J Rheumatol. 2026, 13, 0080, doi: 10.5152/ eurjrheum.2026.25080.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.